MAP2K7 and melanoma: Additionally, a case report of an advanced melanoma patient with SKAP2-BRAF fusion had a partial response to MEK inhibitor monotherapy after progressing on immunotherapy and dacarbazine, though the response was not durable and the patient’s disease ultimately progressed [64].